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Background: Proton pump inhibitors (PPIs) are widely and routinely used to treat gastric acid-related disorders, such 
as gastroesophageal reflux disease (GERD) and peptic ulcer disease, in both inpatient and outpatient settings. Moreover, 
due to the characteristics of the elderly, GERD is one of common geriatric diseases, and then PPIs could be prescribed 
more frequently and longer in the elderly. Thus, in this study, the association between esomeprazole use and the preva-
lence of pneumonia has been evaluated in the elderly. 
Methods: From the National Health Insurance Service-National Sample Cohort database of Korea from 2007 to 2010, 
the elderly were selected and separated into subgroups according to the gender (female vs. male) and GERD (GERD 
vs. non-GERD). Also, esomeprazole was divided into two groups according to the daily dose; ＜40 mg and ≥40 mg. 
Then, the subjects were subdivided according to the duration of esomeprazole treatment; 1 week, 2 weeks, 3 weeks, 
30 days and ≥31 days. Logistic regression was also performed to identify the association between duration of esomepra-
zole administration and pneumonia.
Results: The total of 4,091 elderly subjects were selected. However, the association between the use of esomeprazole 
and the prevalence of pneumonia had been failed to show a significant association (in ＜40 mg esomeprazole group 
P=0.698, 0.504, 0.961 and 0.682 respectively; in ≥40 mg esomeprazole group, P=0.348, 0.846, 0.01and 0.713 re-
spectively) 
Conclusion: The esomeprazole use was not associated with the prevalence of pneumonia in the elderly.
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INTRODUCTION
Proton pump inhibitors (PPIs) are widely and routinely 
used to treat gastric acid-related disorders, such as gastro-
esophageal reflux disease (GERD) and peptic ulcer disease, 
in both inpatient and outpatient settings. Also, GERD is 
considered as one of common geriatric diseases, owing to 
the abnormal peristalsis of the esophagus and dysfunctional 
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production of saliva in the elderly, which in turn makes 
esophageal mucosa vulnerable to the any damage. Thus, 
PPIs are more frequently used in the elderly.1) However, 
there are considerable debates on the PPIs safety, especially 
on the long term use of PPIs due to the efficacy and toler-
ability of them. Some study reported that PPIs have in-
appropriately prescribed and overused in 50∼60% of the 
hospitalized patients.2,3)
Especially, there are numerous studies that have found a 
significant association between PPIs and pneumonia.4-10) One 
study found that patients who were current users of PPIs 
(duration ＜30 days or high dose) had a significant associa-
tion with community-acquired pneumonia (CAP).8) The as-
sociation between PPIs and pneumonia has been hypothe-
sized that the increased gastric pH due to the PPI use may 
facilitate the growth of several bacteria in stomach, where it 
would be sterile with the normal pH of the stomach.7) 
Moreover, this increase in bacteria can lead to pneumonia 
through microaspiration and lung colonization of them.11)
However, two meta-analyses12,13) and another observational 
study14) have shown no significant association between PPI 
use and pneumonia, which, in turn, led to have questions 
about the link. Recently, Estborn et. al have also found that 
the occurrence of respiratory tract infections of patients re-
ceiving esomeprazole was similar to that of those receiving 
placebo.15)
Therefore, considering the circumstance that the elderly 
can be taking many kinds of medication and longer than 
needed, this study was aimed to analyze this controversial 
relationship between CAP and PPIs, especially esomeprazole 
in those who were over 65 years old, with or without 
GERD by using the National Health Insurance Service- 
National Sample Cohort database of Korea from 2007 to 
2010.
MATERIALS AND METHODS
In South Korea, all the Koreans are given a unique iden-
tification numbers and all the nationals are obligated to en-
roll in the Korean National Health Insurance Service 
(KNHIS). With this circumstance, the Korean government 
can collect national wide health information and can release 
representative random subject data, which is so called National 
Sample Cohort database. Further, the KNHIS uses the 
Korean Classification of Diseases (KCD), which is a similar 
system to the International Classification of Diseases 10 
(ICD-10).
In the National Health Insurance Service-National Sample 
Cohort database of Korea from 2007 to 2010, the subjects 
those who had been treated with esomeprazole at least once 
from 2007 to 2010 were included. The exclusion criteria 
were as follows: 1) those who were less than 20 years old; 
2) repeated esomeprazole users from 2007 to 2010; 3) sub-
jects were enrolled after December in 2010. And then, 
more focus was given to those who were over 65 years old 
to see the association between esomeprazole use and CAP.
The definition of Pneumonia and gastroesophageal reflux 
disease (GERD) were based on Korean Classification Disease 
6 (KCD 6; KCD code J09∼18.9, J20∼J22 and J40∼J42 
for pneumonia; KCD code K21.0 and K21.9 for GERD). 
Esomeprazole were restricted to oral agents as pneumonia 
were to community-acquired pneumonia in the outpatient 
setting. The analysis was done with the important opera-
tional definition: pneumonia was limited to the first occur-
rence after taking esomeprazole over 180 days. Then, the 
subjects were subdivided according to the duration of eso-
meprazole treatment as follows: 1 week (reference group for 
logistic regression), 2 weeks, 3 weeks, 30 days, and more 
than 31 days. When subdivided, 30 days of interval be-
tween administrations was considered a new set point to 
count.
The subjects were separated into subgroups according to 
the gender (female vs. male), and GERD (GERD vs. 
non-GERD). Also esomeprazole was divided into two groups 
according to the daily dose; ＜40 mg and ≥40 mg. 
1. Statistical analysis
Mann-Whitney U-test was used to examine the associa-
tion between the total dose of administrated esomeprazole 
and the prevalence of pneumonia. Logistic regression was al-
so performed to identify the association between esomepra-
zole use and pneumonia. (between duration of esomeprazole 
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Table 1. Subgroup analysis in the daily dose of ＜40 mg esomeprazole in the elderly
Duration Non-pneumonia Pneumonia P value* OR 95% CI P value†
Subgroup 1 (65≥age; female; non-GERD)
Total 345 47 0.698
1 week 173 (87.37) 25 (12.63) ref
2 weeks 48 (88.89) 6 (11.11) 0.865 0.336∼2.229 0.764
3 weeks 30 (88.24) 4 (11.76) 0.923 0.300∼52.840 0.888
30 days 73 (91.25) 7 (8.75) 0.664 0.275∼1.602 0.362
≥31 days 21 (80.77) 5 (19.23) 　 1.648 0.570∼4.763 0.357
Subgroup 2 (65≥age; female; GERD)
Total 739 100 0.504
1 week 340 (89.01) 42 (10.99) ref
2 weeks 157 (87.71) 22 (12.29) 1.134 0.655∼1.965 0.653
3 weeks 56 (86.15) 9 (13.85) 1.301 0.600∼2.820 0.505
30 days 149 (89.22) 18 (10.78) 0.978 0.545∼1.755 0.940
≥31 days 37 (80.43) 9 (19.57) 　 1.969 0.888∼4.364 0.095
Subgroup 3 (65≥age; male; non-GERD)
Total 201 36 0.961
1 week 85 (85.86) 14 (14.14) ref
2 weeks 37 (86.05) 6 (13.95) 0.985 0.351∼2.761 0.976
3 weeks 15 (83.33) 3 (16.67) 1.214 0.311∼4.743 0.78
30 days 44 (84.62) 8 (15.38) 1.104 0.430∼2.831 0.837
≥31 days 20 (80) 5 (20) 　 1.519 0.490∼4.707 0.469
Subgroup 4 (65≥age; male; GERD)
Total 478 97 0.682
1 week 193 (80.75) 46 (19.25) ref
2 weeks 115 (83.33) 23 (16.67) 0.839 0.484∼1.456 0.533
3 weeks 45 (86.54) 7 (13.46) 0.653 0.277∼1.541 0.330
30 days 96 (86.49) 15 (13.51) 0.656 0.348∼1.234 0.191
≥31 days 29 (82.86) 6 (17.14) 　 0.868 0.340∼2.213 0.767
GERD: Gastroesophageal reflux disease. *Mann-Whitney U-test. †Logistic regression. 
administration and pneumonia). All Statistical analyses were 
done by using SAS software, version 9.4 (SAS Institute, 
Inc., Cary, NC, USA).
RESULTS
1. Subjects 
Among the subjects those who had been treated with 
esomeprazole at least once from 2007 to 2010 (n= 
4,022,086) those who were less than 20 years old were ex-
cluded (n=3,074,388) and among them, those who had 
gotten administered with esomeprazole for the first time 
were counted (n=26,652) and overlapping subjects were ex-
cluded (n=23,067). Also, the cases where subjects were en-
rolled after December in 2010 were all excluded (n= 
22,163). Finally, the cases in which daily dose frequency 
was 0 in 20 mg of esomeprazole (n=3) and the case in 
which daily dose frequency was 4 in 40 mg of esomeprazole 
(n=1) were eliminated (n=22,159). Then, finally were se-
lected the main subjects who were over 65 years old 
(n=4,091).
2. Analysis in the daily dose of ＜40 mg 
esomeprazole 
In subgroup 1 (65≥age; female; non-GERD), the preva-
lence of pneumonia was not significantly associated with 
esomeprazole use (P=0.698). The OR for 2 weeks, 3 weeks, 
30 days, and ≥30 days of administration were 0.865, 
0.923, 0.664 and 1.648 respectively and none of them were 
found to be statistically significant (P=0.764, 0.888, 0.362 
and 0.357 respectively) (Table 1). 
In subgroup 2 (65≥age; female; GERD), the prevalence 
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Table 2. Subgroup analysis in the daily dose of ≥ 40 mg esomeprazole in the elderly
Duration Non-pneumonia Pneumonia P value* OR 95% CI P value†
Subgroup 1 (65≥age; female; non-GERD)
Total 224 35 0.348
1 week 113 (88.28) 15 (11.72) ref
2 weeks 30 (81.08) 7 (18.92) 1.758 0.658∼4.699 0.261
3 weeks 16 (84.21) 3 (15.79) 1.412 0.368∼5.425 0.615
30 days 49 (83.05) 10 (16.95) 1.537 0.646∼3.661 0.331
≥31 days 16 (100) 0 (0) 　 ＜0.001 ＜0.001∼>999.99 0.978
Subgroup 2 (65≥age; female; GERD)
Total 736 112 0.846
1 week 228 (87.36) 33 (12.64) ref
2 weeks 203 (86.75) 31 (13.25) 1.055 0.624∼1.784 0.842
3 weeks 54 (83.08) 11 (16.92) 1.408 0.669∼2.963 0.368
30 days 205 (86.5) 32 (13.5) 1.078 0.640∼1.817 0.776
≥31 days 46 (90.2) 5 (9.8) 　 0.751 0.279∼2.027 0.573
Subgroup 3 (65≥age; male; non-GERD)
Total 224 30 0.01
1 week 102 (89.47) 12 (10.53) ref
2 weeks 50 (89.29) 6 (10.71) 1.02 0.362∼2.876 0.970
3 weeks 16 (66.67) 8 (33.33) 4.25 1.505∼12.004 0.006
30 days 40 (90.91) 4 (9.09) 0.85 0.259∼2.792 0.789
≥31 days 16 (100) 0 (0) 　 ＜0.001 ＜0.001∼>999.99 0.968
Subgroup 4 (65≥age; male; GERD)
Total 602 85 0.713
1 week 170 (86.29) 27 (13.71) ref
2 weeks 150 (88.76) 19 (11.24) 0.798 0.426∼1.492 0.479
3 weeks 50 (83.33) 10 (16.67) 1.259 0.571∼2.778 0.568
30 days 192 (88.48) 25 (11.52) 0.82 0.458∼1.467 0.503
≥31 days 40 (90.91) 4 (9.09) 　 0.63 0.209∼1.901 0.412
GERD: Gastroesophageal reflux disease. *Mann-Whitney U-test. †Logistic regression.
of pneumonia was not significantly associated with esome-
prazole use (P=0.504). The OR for 2 weeks, 3 weeks, 30 
days, and ≥30 days of administration were 1.134, 1.301, 
0.978 and 1.969 respectively and none of them were found 
to be statistically significant (P=0.653, 0.505, 0.940 and 
0.095 respectively). 
In subgroup 3 (65≥age; male; non-GERD), the preva-
lence of pneumonia was not significantly associated with 
esomeprazole use (P=0.961). The OR for 2 weeks, 3 weeks, 
30 days, and ≥30 days of administration were 0.985, 
1.214, 1.104 and 1.519 respectively and none of them were 
found to be statistically significant (P=0.976, 0.78, 0.837 
and 0.469 respectively). 
In subgroup 4 (65≥age; male; GERD), the prevalence of 
pneumonia was not significantly associated with esomepra-
zole use (P=0.682). The OR for 2 weeks, 3 weeks, 30 
days, and ≥30 days of administration were 0.839, 0.653, 
0.656 and 0.868 respectively. None of them were found to 
be statistically significant (P=0.533, 0.330, 0.191 and 
0.767 respectively).
3. Analysis in the daily dose of ≥40 mg 
esomeprazole 
In subgroup 1 (65≥age; female; non-GERD), the preva-
lence of pneumonia was not significantly associated with 
esomeprazole use (P=0.348). The OR for 2 weeks, 3 weeks, 
30 days, and ≥30 days of administration were 1.758, 
1.412, 1.537 and ＜0.001 respectively and none of them 
were found to be statistically significant (P=0.261, 0.615, 
0.331 and 0.978 respectively) (Table 2). 
In subgroup 2 (65≥age; female; GERD), the prevalence 
of pneumonia was not significantly associated with esome-
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Table 3. The total amount of esomeprazole administration and the prevalence of pneumonia
　 Non-pneumonia
(n=20,013)
Pneumonia
(n=2,146)
P value* OR 95% CI P value† AUC
Cut-off 
point (mg)
Total dose (mg)
Median (min∼max) 280 (20∼6720) 280 (20∼2600) ＜0.001 0.998 0.997∼0.999 ＜0.001 0.524 240
*Mann-Whitney U-test. †Logistic regression Subjects were over 20 years old.
prazole use (P=0.846). The OR for 2 weeks, 3 weeks, 30 
days, and ≥30 days of administration were 1.055, 1.408, 
1.078 and 0.751 respectively and none of them were found 
to be statistically significant (P=0.842, 0.368, 0.776 and 
0.573 respectively). 
In subgroup 3 (65≥age; male; non-GERD), the preva-
lence of pneumonia was significantly associated with esome-
prazole use (P=0.01). The OR for 2 weeks, 3 weeks, 30 
days, and ≥30 days of administration were 1.02, 4.25, 0.85 
and ＜0.001 respectively. Among them, 2 weeks of admin-
istration was found to be statistically significant (P=0.006).
In subgroup 4 (65≥age; male; GERD), the prevalence of 
pneumonia was not significantly associated with esomepra-
zole use (P=0.682). The OR for 2 weeks, 3 weeks, 30 
days, and ≥30 days of administration were 0.798, 1.259, 
0.82 and 0.63 respectively and none of them were found to 
be statistically significant (P=0.479, 0.568, 0.503 and 0.412 
respectively).
4. The association between esomeprazole in 
total dose and the prevalence of pneumonia
The prevalence of pneumonia was significantly decreased 
as the total dose of administrated esomeprazole was in-
creased (Table 3). The odds ratio (OR) was 0.998 with 95% 
Cl (0.997∼0.999) and statistically significant in both Mann- 
Whitney U-test and logistic regression (P＜0.001 both). 
DISCUSSION
Besides of the common adverse effects including head-
ache, nausea, abdominal pain and diarrhea,16,17) the use of 
PPIs has been associated with serval rare adverse effects, 
such as, vitamin B12 deficiency,18-22) iron deficiency.23,24) In 
this study, the association between esomeprazole use and 
CAP was analyzed by using the National Health Insurance 
Service-National Sample Cohort database of Korea from 
2007 to 2010. 
As shown Table 1 and 2, the subjects were subdivided 
by the daily dose of esomeprazole (＜40 mg vs. ≥40 mg) 
and the duration of esomeprazole treatment (1 week, 2 
weeks, 3 weeks, 30 days and ≥31 days) over 65 years old. 
As a result, the association between the use of esomeprazole 
and the prevalence of CAP had been failed to have a sig-
nificant association. The result seemed to be contrary to the 
above hypothetical mechanism of pneumonia due to PPI use 
in other studies. However, one population-based case-control 
study reports that there is not any association between use 
of PPIs and the increased pneumonia risk and concludes 
that the observed increased risk in some study may be due 
to confounding.14) Jena et al. have also reported that the as-
sociation between the PPI use and CAP would be con-
founded and have assessed for that by using the 
‘falsification approach’.25) The results of the study showed 
that similar associations with pneumonia were found in 
chest pain and urinary tract infection. This suggests that al-
though the PPI use and pneumonia appears to have a sig-
nificant association statistically, this could be confounded in 
reality. 
In this study, only male patients who took ≥40 mg of 
esomeprazole daily, were ≥65 years old and did not have 
GERD showed statistically significant association with pneu-
monia with high OR of 3 weeks (OR: 4.25; 95% Cl: 1.505∼
12.004) (Table 2). However, only 3 weeks of duration 
turned out to be statistically significant while others not. 
Thus, without controlling the possible confounding factors, 
this result can be not interpreted as the meaningful out-
come. Moreover, GERD was considered as the confounding 
factor, but the results showed that GERD was not any sig-
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nificant factor. Thus, more compact variables be necessary 
in the future study.
In addition, Giuliano et al.8) reports that those who re-
ceiving PPIs, particularly ＜30 days, showed increased risk 
of CAP. Thus, to examine if there was any the association 
between the total amount of esomeprazole use and CAP, 
the Mann-Whitney U-test and logistic regression were done 
in ages of 20 years and over. If CAP was dose-specific to 
the PPIs, there might be cut-off point, to which the risk of 
CAP would be increased and after which decreased. Table 3 
showed the statistically significant negative association be-
tween esomeprazole in total dose and the prevalence of 
pneumonia over 20 years old. (OR: 0.998; 95% Cl: 0.997∼
0.999). However, the OR (0.998) and AUC (0.524) could 
suggest that the association would be weak, possibly not 
significant in reality, because the numbers indicates that the 
probability of correctly estimating the right pneumonia cases 
with this cut-off point indicates that almost 52%, which 
does not have enough power to evaluate the association be-
tween use of esomeprazole and the prevalence of pneumonia 
in this study. Thus, it could not be said that esomeprazole 
use and CAP were on negative association based on this re-
sult even though it appeared statistically significant. This 
negative tendency could be also explained by the possible 
bias from the huge number of participants being analyzed. 
Despite of the huge sample size, the major limitations of 
this study were the lack of demographic and health charac-
teristics of subjects - so the effects of any differences such as 
diabetes, chronic obstructive pulmonary disease, and smoking 
etc. in them could not be analyzed, which would hopefully 
be expected to give us the exponible confounding factors in 
the association - ; no true control groups such as those who 
had not taken any PPIs in each analyses, even though the 
7 days of PPI use was considered a reference; and only eso-
meprazole has been included in this study. Thus, in future 
study, the true control group in which no PPIs and no H2 
blockers are administered should be selected to compare and 
all the available PPIs should be included so as to better 
evaluate the relationship between PPI use and the risk of 
pneumonia. 
Lastly, this study was the first to evaluate the PPIs use 
and the risk of CAP by using Korean National Sample 
Cohort database, but to fail to reveal any significant associa-
tion between the esomeprazole use and the prevalence of 
pneumonia in the elderly. 
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